The FDA scheduled a hearing on peptides and the implications could be significant for prescribers and FDA issued its first warning letter to a dispenser (a medical spa) for violating the Drug Supply Chain Security Act (DSCSA), including failing to source products from authorized trading partners and The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications, and Future Perspectives BPC 157: Experimental Peptide Creates Risk for Athletes The Peptide Craze Part 2: BPC 157, NAD and the Truth Behind the Longevity Molecule Hype